Assenagon Asset Management
PACB icon

Assenagon Asset Management’s Pacific Biosciences PACB Stock Holding History

Assenagon Asset Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-213,091
Closed -$390K – 1297
2024
Q4 		$390K Sell
213,091
-68,796
-24% -$134K ﹤0.01% 1227
2024
Q3 		$479K Sell
281,887
-1,013,416
-78% -$1.67M ﹤0.01% 1250
2024
Q2 		$1.77M Buy
+1,295,303
New +$2.62M ﹤0.01% 945
2024
Q1 		– Sell
-3,041,624
Closed -$29.8M – 1453
2023
Q4 		$29.8M Buy
3,041,624
+2,909,439
+2,201% +$23.8M 0.08% 199
2023
Q3 		$1.1M Buy
+132,185
New +$1.51M ﹤0.01% 1015
2023
Q2 		– Sell
-11,292
Closed -$131K – 1433
2023
Q1 		$131K Sell
11,292
-238,838
-95% -$2.37M ﹤0.01% 1380
2022
Q4 		$2.05M Sell
250,130
-545
-0.2% -$4.7K 0.01% 804
2022
Q3 		$1.46M Hold
250,675
– – 0.01% 812
2022
Q2 		$1.11M Buy
+250,675
New +$1.52M ﹤0.01% 1049
2022
Q1 		– Sell
-48,822
Closed -$999K – 1525
2021
Q4 		$999K Buy
48,822
+16,281
+50% +$393K ﹤0.01% 1036
2021
Q3 		$831K Sell
32,541
-47,457
-59% -$1.41M ﹤0.01% 952
2021
Q2 		$2.8M Sell
79,998
-543,073
-87% -$15.8M 0.01% 601
2021
Q1 		$20.8M Sell
623,071
-12,997
-2% -$455K 0.08% 211
2020
Q4 		$16.5M Sell
636,068
-234,203
-27% -$3.98M 0.07% 180
2020
Q3 		$8.59M Sell
870,271
-118,913
-12% -$685K 0.05% 220
2020
Q2 		$3.41M Sell
989,184
-542,166
-35% -$1.85M 0.02% 432
2020
Q1 		$4.69M Buy
+1,531,350
New +$6.27M 0.04% 238
2019
Q4 		– Sell
-980,997
Closed -$5.06M – 890
2019
Q3 		$5.06M Buy
+980,997
New +$5.49M 0.03% 235
2019
Q1 		– Sell
-116,302
Closed -$861K – 1062
2018
Q4 		$861K Buy
+116,302
New +$737K 0.01% 694

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management's PACB Position: Q1 2025 in Review

Assenagon Asset Management sold out of Pacific Biosciences (PACB) in Q1 2025, closing a stake of 213,091 shares — an estimated $390K sold.

Assenagon Asset Management first reported a position in PACB in Q4 2018 and held it in 19 quarters. The position peaked at $29.8M in Q4 2023. 225 funds tracked by Wall St. Rank hold PACB as of Q1 2025.

  • Assenagon Asset Management reported no remaining Pacific Biosciences position as of Q1 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 213,091 Pacific Biosciences shares in Q1 2025, an estimated $390K.
  • Assenagon Asset Management first reported a position in Pacific Biosciences in Q4 2018 and held it in 19 quarters.
  • Assenagon Asset Management's Pacific Biosciences position peaked at $29.8M in Q4 2023.
  • 225 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2025.

Based on Assenagon Asset Management's 13F filing for Q1 2025, filed 15 Apr 2025.